



General Assembly

February Session, 2016

Raised Bill No. 129

LCO No. 1239



Referred to Committee on PUBLIC HEALTH

Introduced by:
(PH)

***AN ACT CONCERNING INSURANCE COVERAGE FOR ABUSE-
DETERRENT OPIOID ANALGESICS.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. (NEW) (*Effective January 1, 2017*) (a) As used in this
2 section, (1) "opioid analgesic" means a drug product that contains an
3 opioid agonist and is approved by the federal Food and Drug
4 Administration for the treatment of pain, whether in immediate release
5 or extended release form, and whether or not combined with other
6 drug substances to form a single drug product or dosage, and (2)
7 "abuse-deterrent opioid analgesic" means an opioid analgesic with
8 labeling that indicates the drug's abuse-deterrent properties are
9 expected to deter or reduce the abuse of such drug.
- 10 (b) Each insurance company, health care center, hospital service
11 corporation, medical service corporation, fraternal benefit society or
12 other entity that delivers, issues for delivery, renews, amends or
13 continues any individual health insurance policy providing coverage
14 of the type specified in subdivisions (1), (2), (4), (11), (12) and (16) of
15 section 38a-469 of the general statutes and that provides coverage for

16 prescription drugs shall provide coverage for at least one abuse-
17 deterrent opioid analgesic per opioid analgesic active ingredient.

18 (c) Notwithstanding subdivision (2) of subsection (a) and
19 subdivision (1) of subsection (b) of section 38a-510 of the general
20 statutes, no such company, center, corporation, society or other entity
21 shall require an insured to use a non-abuse-deterrent opioid analgesic
22 prior to using an abuse-deterrent opioid analgesic.

23 Sec. 2. (NEW) (*Effective January 1, 2017*) (a) As used in this section,
24 (1) "opioid analgesic" means a drug product that contains an opioid
25 agonist and is approved by the federal Food and Drug Administration
26 for the treatment of pain, whether in immediate release or extended
27 release form, and whether or not combined with other drug substances
28 to form a single drug product or dosage, and (2) "abuse-deterrent
29 opioid analgesic" means an opioid analgesic with labeling that
30 indicates the drug's abuse-deterrent properties are expected to deter or
31 reduce the abuse of such drug.

32 (b) Each insurance company, health care center, hospital service
33 corporation, medical service corporation, fraternal benefit society or
34 other entity that delivers, issues for delivery, renews, amends or
35 continues any group health insurance policy providing coverage of the
36 type specified in subdivisions (1), (2), (4), (11), (12) and (16) of section
37 38a-469 of the general statutes and that provides coverage for
38 prescription drugs shall provide coverage for at least one abuse-
39 deterrent opioid analgesic per opioid analgesic active ingredient.

40 (c) Notwithstanding subdivision (2) of subsection (a) and
41 subdivision (1) of subsection (b) of section 38a-544 of the general
42 statutes, no such company, center, corporation, society or other entity
43 shall require an insured to use a non-abuse-deterrent opioid analgesic
44 prior to using an abuse-deterrent opioid analgesic.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2017</i>	New section
Sec. 2	<i>January 1, 2017</i>	New section

Statement of Purpose:

To require insurance coverage for abuse-deterrent opioid analgesics.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]